Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy

Andrés J.M. Ferreri, Maurilio Ponzoni, Massimo Guidoboni, Carlo De Conciliis, Antonio Giordano Resti, Benedetta Mazzi, Antonia Anna Lettini, Judit Demeter, Stefania Dell'Oro, Claudio Doglioni, Eugenio Villa, Mauro Boiocchi, Riccardo Dolcetti

Research output: Article

174 Citations (Scopus)

Abstract

Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80% of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas. Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up. Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50%) was observed in two patients, and minimal response (< 50%) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively. Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.

Original languageEnglish
Pages (from-to)5067-5073
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number22
DOIs
Publication statusPublished - dec. 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ferreri, A. J. M., Ponzoni, M., Guidoboni, M., De Conciliis, C., Resti, A. G., Mazzi, B., Lettini, A. A., Demeter, J., Dell'Oro, S., Doglioni, C., Villa, E., Boiocchi, M., & Dolcetti, R. (2005). Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. Journal of Clinical Oncology, 23(22), 5067-5073. https://doi.org/10.1200/JCO.2005.07.083